Medical News

RSS

Bionomics files novel angiogenesis genes patent

Bionomics Limited has announced that it had filed a further international patent application that covers 496 proprietary angiogenesis drug targets. The international patent application applies to genes that Bionomics has identified using advanced technologies such as microarray and bioinformatics analyses. These technologies have enabled Bionomics to identify novel angiogenesis genes that have not been identified by other companies or research groups.

26 Mar 2004

Growth factor protein succeeds in growing new coronary arteries

Three patients of the UC Heart & Vascular Center have grown new coronary artery branches to increase blood flow to the heart after receiving a new growth factor protein (FGF1) in November 2003. All three patients showed improved blood flow to the heart twelve weeks following the injection.

26 Mar 2004

Super glue and vascular graft surgery

Got a broken teacup, an art project, or a leaky blood vessel? “Super glue” it. Surgeons at Baylor College of Medicine in Houston are studying whether a liquid sealant, similar to common household “super glue,” forms a tight seal around blood vessels used in vascular graft surgery.

25 Mar 2004

Thyroid disorders are often misdiagnosed

Thyroid disorders are among the most common medical conditions. However, because their symptoms often appear gradually, the condition is often misdiagnosed, according to Dr. Nila Vora, a board-certified endocrinologist at the Loyola Primary Care Center in Darien.

25 Mar 2004

Children with sickle cell disease are living longer, dying less often from their disease

Children with sickle cell disease, an inherited red blood-cell disorder, are living longer, dying less often from their disease and contracting fewer fatal infections than ever before, researchers at UT Southwestern Medical Center at Dallas report. Their study, which will appear in the June edition of the scientific journal Blood, is the first to evaluate survival rates of children receiving the most modern treatments for sickle cell disease. It's also one of the largest published sickle cell studies to date. Researchers followed more than 700 Dallas-area children with the disease over two decades.

25 Mar 2004

Joint Research Collaboration to Predict 3-D Protein Structures and Support Drug Discovery

IBM today announced that the University at Buffalo (UB) Center of Excellence in Bioinformatics, The State University of New York, will use IBM technologies and research expertise to study the structure and behavior of human proteins. The outcome of this research could lead to more targeted drugs to treat diseases such as cancer, Alzheimer's, AIDS and multiple sclerosis.

25 Mar 2004

Researchers turn off individual human genes to study their function

Researchers have produced vast libraries of short segments of ribonucleic acid (RNA) that can be used to turn off individual human and mouse genes to study their function. The libraries will be made widely available to laboratories studying human biology and disease. The researchers are optimistic that the libraries will become a powerful research tool for gene analysis and discovery.

25 Mar 2004

Stenting for Stroke Prevention is More Effective Than Surgery in Keeping Blood Vessels Open

Research presented in a six-hour symposium on carotid artery disease at the 29th Annual Scientific Meeting of the Society of Interventional Radiology showed carotid artery stenting to be safe and effective for highrisk patients. Currently, the standard of care for stroke prevention in patients with moderate to severely blocked carotid arteries is carotid endarterectomy surgery. The ARCHeR trials treated patients who were high-risk surgical candidates with carotid artery stenting with and without embolic protection, a device to capture debris that may break off during the procedure.

25 Mar 2004

Alfuzosin, new treatment for Acute Urinary Retention

The results of the ALFAUR (ALFuzosin in Acute Urinary Retention) study, announced today at the XIXth European Association of Urology (EAU) Congress in Vienna, Austria, indicate that the uroselective alpha1-blocker alfuzosin 10 mg once daily (OD) may have a beneficial effect in the management of male patients suffering from acute urinary retention (AUR), a sudden inability to pass urine that results in a painful distension of the bladder, requires immediate management with urethral catheterization and could necessitate surgical intervention.

25 Mar 2004

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004

Discovery of new gene sheds light on human brain development

With the identification of the gene responsible for a newly recognized type of mental retardation, researchers at Beth Israel Deaconess Medical Center (BIDMC) have also discovered what appears to be the key target in the evolution of the frontal lobes of the brain's cerebral cortex. The findings offer a key insight into the complex puzzle of human brain development - and the evolution of human behavior.

25 Mar 2004

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.

25 Mar 2004

A debate over the origins of what is sometimes called "junk" DNA has been settled

A debate over the origins of what is sometimes called "junk" DNA has been settled by research involving scientists at the Center for Advanced Research in Biotechnology (CARB) and a collaborator, who developed rigorous proof that these mysterious sections were added to DNA "late" in the evolution of life on earth, after the formation of modern-sized genes, which contain instructions for making proteins.

25 Mar 2004

Asthma study turns up new information on viral infections

Researchers know that viral infections can exacerbate asthma and, in turn, make people with the condition more sensitive to environmental exposures such as endotoxin. But how viral infections contribute to this sensitivity in airway cells has not been clear. A recent study led by investigators from the University of Iowa Roy J. and Lucille A. Carver College of Medicine and the Veterans Affairs Medical Center (VAMC) in Iowa City shows, for the first time, that viral infections may increase environmental sensitivity in lung epithelial (surface) cells by changing expression of receptors on those cells.

25 Mar 2004

Approval for FOSRENOL (lanthanum carbonate), which controls phosphate levels in renal dialysis patients

Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in securing marketing approval throughout Europe. A submission has also been made by Shire to gain marketing approval for FOSRENOL in the United States.

25 Mar 2004

Scientists discover a method to detect trace levels of swine antibiotics in the groundwater.

Scientists from the Department of Soil, Water, & Climate at University of Minnesota have developed a simple method to quantify two types of antibiotics in animal manures, and surface and ground waters. Chlortetracycline and tylosin antibiotics are commonly used for growth promotion in swine production.

25 Mar 2004

Breakthrough studies that could lead to a new means of combating malaria

EMBL scientists have identified four mosquito proteins that affect the ability of the malaria parasite (Plasmodium) to survive and develop in the malaria-carrier mosquito (Anopheles). This breakthrough could be used to block the transmission of malaria from mosquitoes to humans.

25 Mar 2004

Scientists have taken a significant leap forward in understanding the complex ways that molecules work together in cells.

Although scientists already know a lot about single molecules, they know very little about how they are assembled into larger molecular complexes or "machines" and how these machines work together to create a complete, functioning cell. The problem is like trying to assemble a puzzle with billions of pieces– with only the shapes of some pieces to go on.

25 Mar 2004

Brain signals could act as remote controls

In their first human studies of the feasibility of using brain signals to operate external devices, researchers at Duke University Medical Center report that arrays of electrodes can provide useable signals for controlling such devices. The research team is now working to develop prototype devices that may enable paralyzed people to operate "neuroprosthetic" and other external devices using only their brain signals.

25 Mar 2004

iCAD issued with Fulcrum mammography film digitizer patent

iCAD, Inc., which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications, today announced that the U.S. Patent and Trademark Office has issued the Company two patents for its Fulcrum mammography film digitizer and technology.

24 Mar 2004